YouTube as a Source of Influenza Vaccine Information in Spanish
Abstract
:1. Introduction
- RQ 1: What are the general characteristics of the videos?
- RQ 2: What are the temporal distribution and the positive tone of the videos?
- RQ 3: What is the information related to the influenza vaccine discussed in the videos?
- RQ 4: What are the hoaxes and conspiracy theories related to the influenza vaccine discussed in the videos, and when and by whom were such videos published?
- RQ 5: Is there any relationship between the type of authorship of the video and the year of publication, number of views/likes/dislikes/comments, duration, type of publication, positive tone of the message, and information discussed regarding the influenza vaccine?
- RQ 6: Is there any relationship between the country of publication of the video and the year of publication, number of views/likes/dislikes/comments, duration, type of publication, positive tone of the message, and information discussed regarding the influenza vaccine?
2. Materials and Methods
3. Results
3.1. RQ 1: What Are the General Characteristics of the Videos?
3.2. RQ 2: What Are the Temporal Distribution and the Positive Tone of the Videos?
3.3. RQ 3: What Is the Information Related to the Influenza Vaccine Discussed in the Videos?
3.4. RQ 4: What Are the Hoaxes and Conspiracy Theories Related to the Influenza Vaccine Discussed in the Videos, and When and by Whom Were Such Videos Published?
3.5. RQ 5: Is There Any Relationship between the Type of Authorship of the Video and the Year of Publication, Number of Views/Likes/Dislikes/Comments, Duration, Type of Publication, Positive Tone of the Message, and Information Discussed Regarding the Influenza Vaccine?
3.6. RQ 6: Is There Any Relationship between the Country of Publication of the Video and the Year of Publication, Number of Views/Likes/Dislikes/Comments, Duration, Type of Publication, Positive Tone of the Message, and Information Discussed Regarding the Influenza Vaccine?
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Stokel-Walker, C. Covid-19: The doctors turned YouTubers. BMJ 2020, 369, m1563. [Google Scholar] [CrossRef] [PubMed]
- Madathil, K.C.; Rivera-Rodriguez, A.J.; Greenstein, J.S.; Gramopadhye, A.K. Healthcare information on YouTube: A systematic review. Health Inform. J. 2015, 21, 173–194. [Google Scholar] [CrossRef] [PubMed]
- Covolo, L.; Ceretti, E.; Passeri, C.; Boletti, M.; Gelatti, U. What arguments on vaccinations run through YouTube videos in Italy? A content analysis. Hum. Vaccin. Immunother. 2017, 13, 1693–1699. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- García, A.; Fernández Prada, M.; Aristegui, J.; Moreno, D.; Redondo, E.; Jimeno, I.; García Cenoz, M.; López Trigo, J.A. Documento de Actualización y Reflexión Sobre la Vacunación Antigripal en España, 1st ed.; Esmon Publicidad: Barcelona, Spain, 2018; ISBN 978-84-17394-12-7. [Google Scholar]
- Yuksel, B.; Cakmak, K. Healthcare Information on YouTube: Pregnancy and COVID-19. Int. J. Gynaecol. Obstet. 2020. [Google Scholar] [CrossRef] [PubMed]
- Gonsalves, G.; Staley, P. Panic, paranoia, and public health—The AIDS epidemic’s lessons for Ebola. N. Engl. J. Med. 2014, 371, 2348–2349. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aquino, F.; Donzelli, G.; De Franco, E.; Privitera, G.; Lopalco, P.L.; Carducci, A. The web and public confidence in MMR vaccination in Italy. Vaccine 2017, 35 Pt B, 4494–4498. [Google Scholar] [CrossRef]
- Donzelli, G.; Palomba, G.; Federigi, I.; Aquino, F.; Cioni, L.; Verani, M.; Carducci, A.; Lopalco, P. Misinformation on vaccination: A quantitative analysis of YouTube videos. Hum. Vaccin. Immunother. 2018, 14, 1654–1659. [Google Scholar] [CrossRef] [Green Version]
- Eysenbach, G. Infodemiology: The epidemiology of (mis)information. Am. J. Med. 2002, 113, 763–765. [Google Scholar] [CrossRef]
- Eysenbach, G. Infodemiology and infoveillance: Framework for an emerging set of public health informatics methods to analyze search, communication and publication behavior on the Internet. J. Med. Internet Res. 2009, 11, e11. [Google Scholar] [CrossRef]
- Yiannakoulias, N.; Slavik, C.; Chase, M. Expressions of pro- and anti-vaccine sentiment on YouTube. Vaccine 2019, 37, 2057–2064. [Google Scholar] [CrossRef]
- Ekram, S.; Debiec, K.E.; Pumper, M.A.; Moreno, M.A. Content and Commentary: HPV Vaccine and YouTube. J. Pediatr. Adolesc. Gynecol. 2019, 32, 153–157. [Google Scholar] [CrossRef] [PubMed]
- Basch, C.H.; Zybert, P.; Reeves, R.; Basch, C.E. What do popular YouTubeTM videos say about vaccines? Child Care Health Dev. 2017, 43, 499–503. [Google Scholar] [CrossRef] [PubMed]
- Hernández-García, I.; Ragozzino, S.; Giménez-Júlvez, T. Characteristics of YouTube videos about the meningococcal B vaccine (4CMenB). Hum. Vaccin. Immunother. 2020, 16, 2513–2517. [Google Scholar] [CrossRef] [PubMed]
- Briones, R.; Nan, X.; Madden, K.; Waks, L. When vaccines go viral: An analysis of HPV vaccine coverage on YouTube. Health Commun. 2012, 27, 478–485. [Google Scholar] [CrossRef] [PubMed]
- Pandey, A.; Patni, N.; Singh, M.; Sood, A.; Singh, G. YouTube as a Source of Information on the H1N1 Influenza Pandemic. Am. J. Prev. Med. 2010, 38, e1–e3. [Google Scholar] [CrossRef]
- Kallur, A.; Albalbissi, A.; Carillo-Martin, I.; Boonpheng, B.; Kallur, L.; Kherallah, Y.; Mahajan, A.; Mahapatra, S.; Mohan, K.; Mohan, P.; et al. Doctor YouTube’s opinion on seasonal influenza: A critical appraisal of the information available to patients. Digit. Health 2020, 6. [Google Scholar] [CrossRef]
- Hernández-García, I.; Tarancón-Cebrián, I. Characteristics of YouTube videos in Spanish about the influenza vaccine. An. Sist. Sanit. Navar. 2020, 43, 35–41. [Google Scholar] [CrossRef]
- Basch, C.H.; Hillyer, G.C.; Meleo-Erwin, Z.C.; Jaime, C.; Mohlman, J.; Basch, C.E. Preventive Behaviors Conveyed on YouTube to Mitigate Transmission of COVID-19: Cross-Sectional Study. JMIR Public Health Surveill. 2020, 6, e18807. [Google Scholar] [CrossRef]
- Mueller, S.M.; Jungo, P.; Cajacob, L.; Schwegler, S.; Itin, P.; Brandt, O. The Absence of Evidence is Evidence of Non-Sense: Cross-Sectional Study on the Quality of Psoriasis-Related Videos on YouTube and Their Reception by Health Seekers. J. Med. Internet Res. 2019, 21, e11935. [Google Scholar] [CrossRef]
- Basch, C.H.; Hillyer, G.C.; Zagnit, E.A.; Basch, C.E. YouTube coverage of COVID-19 vaccine development: Implications for awareness and uptake. Hum. Vaccin. Immunother. 2020. [Google Scholar] [CrossRef]
- Hernández-García, I.; Giménez-Júlvez, T. Characteristics of YouTube Videos in Spanish on How to Prevent COVID-19. Int. J. Environ. Res. Public Health 2020, 17, 4671. [Google Scholar] [CrossRef] [PubMed]
- Keelan, J.; Pavri-Garcia, V.; Tomlinson, G.; Wilson, K. YouTube as a source of information on immunization: A content analysis. JAMA 2007, 298, 2482–2484. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tuells, J.; Martínez-Martínez, P.J.; Duro-Torrijos, J.L.; Caballero, P.; Fraga-Freijeiro, P.; Navarro-López, V. Characteristics of the Videos in Spanish Posted on Youtube about Human Papillomavirus Vaccines. Rev. Esp. Salud Publica 2015, 89, 107–115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hernández-García, I.; Fernández Porcel, C. Characteristics of YouTube™ videos in Spanish about the vaccine against meningococcus B. Vacunas 2018, 19, 37–43. [Google Scholar] [CrossRef]
- Organización Mundial de la Salud. Preguntas y Respuestas Sobre Inmunización y Seguridad de las Vacunas. Available online: https://www.who.int/features/qa/84/es/ (accessed on 10 November 2020).
- Organización Mundial de la Salud. Gripe (Estacional). Available online: https://www.who.int/es/news-room/fact-sheets/detail/influenza-(seasonal) (accessed on 9 November 2020).
- Ministerio de Sanidad. Recomendaciones de Vacunación Frente a la Gripe: Temporada 2020–2021. Available online: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/docs/Recomendaciones_vacunacion_gripe.pdf (accessed on 18 October 2020).
- Grohskopf, L.A.; Alyanak, E.; Broder, K.R.; Walter, E.B.; Fry, A.M.; Jernigan, D.B. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2019–2020 Influenza Season. MMWR Recomm. Rep. 2019, 68, 1–21. [Google Scholar] [CrossRef] [Green Version]
- Gentile, A.; Paget, J.; Bellei, N.; Torres, J.P.; Vazquez, C.; Laguna-Torres, V.A.; Plotkin, S. Influenza in Latin America: A report from the Global Influenza Initiative (GII). Vaccine 2019, 37, 2670–2678. [Google Scholar] [CrossRef]
- Ropero-Álvarez, A.M.; El Omeiri, N.; Kurtis, H.J.; Danovaro-Holliday, M.C.; Ruiz-Matus, C. Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic. Hum. Vaccin. Immunother. 2016, 12, 2206–2214. [Google Scholar] [CrossRef] [Green Version]
- World Health Organization. Vaccination of Health Care Workers Recommended. Available online: http://www.who.int/immunization/policy/Immunization_routine_table4.pdf (accessed on 19 October 2020).
- Ministerio de Salud de Chile. Campaña de Vacunación Contra la Influenza 2019: Ponle el Hombro al Invierno. Available online: https://www.minsal.cl/vacunacion-contra-la-influenza/ (accessed on 12 November 2020).
- Barratt, J.; Mishra, V.; Acton, M. Latin American Adult Immunisation Advocacy Summit: Overcoming regional barriers to adult vaccination. Aging Clin. Exp. Res. 2019, 31, 339–344. [Google Scholar] [CrossRef]
- Ministerio de Sanidad. Coberturas de Vacunación: Datos Estadísticos. Available online: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/coberturas/home.htm (accessed on 14 November 2020).
- Thomson, A.; Watson, M. Vaccine hesitancy: A vade mecum v1.0. Vaccine 2016, 34, 1989–1992. [Google Scholar] [CrossRef] [Green Version]
- Dunn, A.G.; Leask, J.; Zhou, X.; Mandl, K.D.; Coiera, E. Associations between Exposure to and Expression of Negative Opinions about Human Papillomavirus Vaccines on Social Media: An Observational Study. J. Med. Internet Res. 2015, 17, e144. [Google Scholar] [CrossRef]
- Cuan-Baltazar, J.; Muñoz-Perez, M.J.; Robledo-Vega, C.; Pérez-Zepeda, M.F.; Soto-Vega, E. Misinformation of COVID-19 on the internet: Infodemiology study. JMIR Public Health Surveill. 2020, 6, e18444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rovetta, A.; Bhagavathula, A.S. COVID-19-related web search behaviors and infodemic attitudes in Italy: Infodemiological study. JMIR Public Health Surveill. 2020, 6, e19374. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. 5 Myths about the Flu Vaccine. Available online: https://www.who.int/news-room/spotlight/influenza-are-we-ready/5-myths-about-the-flu-vaccine (accessed on 27 August 2020).
- Venkatraman, A.; Garg, N.; Kumar, N. Greater freedom of speech on Web 2.0 correlates with dominance of views linking vaccines to autism. Vaccine 2015, 33, 1422–1425. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Frequency, n (%) |
---|---|
Country of publication | |
Mexico | 24 (24.0) |
Argentina | 17 (17.0) |
Spain | 16 (16.0) |
Chile | 13 (13.0) |
The United States of America | 11 (11.0) |
Colombia | 3 (3.0) |
Peru | 3 (3.0) |
Nicaragua | 2 (2.0) |
Costa Rica | 2 (2.0) |
France | 2 (2.0) |
Paraguay | 1 (1.0) |
Panama | 1 (1.0) |
Canada | 1 (1.0) |
Russia | 1 (1.0) |
Unknown | 3 (3.0) |
Type of authorship | |
Mass media | 51 (51.0) |
Health professionals | 23 (23.0) |
User-generated content | 20 (20.0) |
Others | 6 (6.0) |
Type of publication | |
News | 36 (36.0) |
Material created by the user | 34 (34.0) |
Interviews | 18 (18.0) |
Advertisements | 8 (8.0) |
Conferences | 2 (2.0) |
Documentaries | 2 (2.0) |
Year of Publication | Frequency, n (%) |
---|---|
2015 | 9 (9.0) |
2016 | 11 (11.0) |
2017 | 14 (14.0) |
2018 | 18 (18.0) |
2019 | 20 (20.0) |
2020 | 28 (28.0) |
Information Related to the Influenza Vaccine | Discussed, n (%) | Not Discussed, n (%) |
---|---|---|
Benefits of the vaccine | 59 (59.0) | 41 (41.0) |
Adverse effects of the vaccine | 39 (39.0) | 61 (61.0) |
Recommendations for any trimester of pregnancy | 36 (36.0) | 64 (64.0) |
Recommendations for people aged 65 years of age or older | 27 (27.0) | 73 (73.0) |
Recommendations for people with chronic lung diseases | 26 (26.0) | 74 (74.0) |
Recommendations for people with diabetes mellitus | 21 (21.0) | 79 (79.0) |
Recommendations for people with chronic cardiovascular diseases | 20 (20.0) | 80 (80.0) |
Hoaxes and conspiracy theories | 19 (19.0) | 81 (81.9) |
Recommendations for healthcare workers | 18 (18.0) | 82 (82.0) |
Costs of the vaccine | 18 (18.0) | 82 (82.0) |
Recommendations for children of 6 months to 5 years | 17 (17.0) | 83 (83.0) |
Recommendations for people with cancer | 14 (14.0) | 86 (86.0) |
Description of the dosage | 14 (14.0) | 86 (86.0) |
Recommendations for people with obesity | 13 (13.0) | 87 (87.0) |
Recommendations for people of 60 or more years | 11 (11.0) | 89 (89.0) |
Recommendations for all people older than 6 months | 11 (11.0) | 89 (89.0) |
Recommendations for children aged 6 months to 2 years | 10 (10.0) | 90 (90.0) |
Recommendations for people with HIV a | 9 (9.0) | 91 (91.0) |
Recommendations for people with chronic kidney disease | 7 (7.0) | 93 (93.0) |
Recommendations for pregnant women from 13 weeks of gestation | 5 (5.0) | 95 (95.0) |
Recommendations for children aged 6 months to 6 years | 3 (3.0) | 97 (97.0) |
Recommendations for children aged 6 months to 10 years | 3 (3.0) | 97 (97.0) |
|
|
|
Tone | Type of Authorship | Available, n (%) | Unavailable, n (%) | OR (95% CI) a | p |
---|---|---|---|---|---|
Positive tone of the message | Mass media | 36 (55.4) | 15 (42.9) | 0.36 (0.09–1.39) | 0.155 |
User-generated content | 4 (6.2) | 16 (45.7) | 0.04 (0.01–0.19) | 0.000 | |
Others | 5 (7.7) | 1 (2.9) | 0.75 (0.06–8.83) | 1.000 | |
Health professionals | 20 (30.7) | 3 (8.5) | 1 |
Information Regarding Influenza Vaccine | Type of Authorship | Available, n (%) | Unavailable, n (%) | OR (95% CI) a | p |
---|---|---|---|---|---|
Benefits of the vaccine | Mass media | 35 (59.3) | 16 (39.1) | 0.77 (0.26–2.33) | 0.648 |
User-generated content | 3 (5.1) | 17 (41.5) | 0.06 (0.01–0.29) | 0.000 | |
Others | 4 (6.8) | 2 (4.9) | 0.71 (0.10–4.89) | 1.000 | |
Health professionals | 17 (28.8) | 6 (14.6) | 1 | ||
Adverse effects of the vaccine | Mass media | 17 (43.6) | 34 (55.7) | 0.78 (0.28–2.16) | 0.631 |
User-generated content | 13 (33.3) | 7 (11.5) | 2.89 (0.83–10.02) | 0.094 | |
Others | 0 (0) | 6 (9.8) | - | 0.138 | |
Health professionals | 9 (23.1) | 14 (23.0) | 1 | ||
Recommendations for pregnancy b | Mass media | 23 (56.1) | 28 (47.5) | 0.63 (0.23–1.70) | 0.366 |
User-generated content | 2 (4.9) | 18 (30.5) | 0.09 (0.02–0.46) | 0.002 | |
Others | 3 (7.3) | 3 (5.1) | 0.77 (0.13–4.66) | 1.000 | |
Health professionals | 13 (31.7) | 10 (16.9) | 1 | ||
Recommendations for children c | Mass media | 19 (57.6) | 32 (47.8) | 0.54 (0.20–1.47) | 0.232 |
User-generated content | 0 (0) | 20 (29.9) | - | 0.000 | |
Others | 2 (6.0) | 4 (6.0) | 0.46 (0.07–3.02) | 0.651 | |
Health professionals | 12 (36.4) | 11 (16.4) | 1 | ||
Recommendations for people aged 60/65 years or older | Mass media | 19 (50.0) | 32 (51.6) | 0.46 (0.17–1.24) | 0.124 |
User-generated content | 2 (5.3) | 18 (29.0) | - | 0.002 | |
Others | 4 (10.5) | 2 (3.2) | 1.54 (0.23–10.15) | 1.000 | |
Health professionals | 13 (34.2) | 10 (16.1) | 1 | ||
Recommendations for people with chronic lung diseases | Mass media | 11 (52.4) | 40 (50.6) | 0.99 (0.29–3.27) | 0.987 |
User-generated content | 2 (9.5) | 18 (22.8) | 0.4 (0.07–2.34) | 0.421 | |
Others | 3 (14.3) | 3 (3.8) | 3.6 (0.55–23.65) | 0.305 | |
Health professionals | 5 (23.8) | 18 (22.8) | 1 | ||
Recommendations for people with chronic cardiovascular disease | Mass media | 12 (60.0) | 39 (48.8) | 1.46 (0.42–5.14) | 0.762 |
User-generated content | 2 (10.0) | 18 (22.5) | 0.53 (0.09–3.24) | 0.669 | |
Others | 2 (10.0) | 4 (5.0) | 2.38 (0.32–17.74) | 0.575 | |
Health professionals | 4 (20.0) | 19 (23.8) | 1 | ||
Recommendations for people with cancer | Mass media | 9 (64.3) | 42 (48.8) | 1.43 (0.35–5.86) | 0.743 |
User-generated content | 1 (7.1) | 19 (22.1) | 0.35 (0.04–3.67) | 0.611 | |
Others | 1 (7.1) | 5 (5.8) | 1.33 (0.11–15.71) | 1.000 | |
Health professionals | 3 (21.4) | 20 (23.3) | 1 | ||
Recommendations for people with obesity | Mass media | 9 (69.2) | 42 (48.3) | 1.43 (0.35–5.86) | 0.743 |
User-generated content | 0 (0) | 20 (23.0) | - | 0.236 | |
Others | 1 (7.7) | 5 (5.7) | 1.33 (0.11–15.71) | 1.000 | |
Health professionals | 3 (23.1) | 20 (23.0) | 1 | ||
Recommendations for healthcare workers | Mass media | 12 (66.7) | 39 (47.5) | 1.46 (0.42–5.14) | 0.762 |
User-generated content | 0 (0) | 20 (24.4) | - | 0.111 | |
Others | 2 (11.1) | 4 (4.9) | 2.38 (0.32–17.74) | 0.575 | |
Health professionals | 4 (22.2) | 19 (23.2) | 1 | ||
Recommendations for people with HIV d | Mass media | 7 (77.8) | 44 (48.4) | 3.5 (0.41–30.26) | 0.422 |
User-generated content | 0 (0) | 20 (22.0) | - | 1.000 | |
Others | 1 (11.1) | 5 (5.5) | 4.4 (0.23–82.98) | 0.377 | |
Health professionals | 1 (11.1) | 22 (24.1) | 1 | ||
Recommendations for people with chronic kidney disease | Mass media | 5 (71.4) | 46 (49.5) | 2.39 (0.26–21.72) | 0.659 |
User-generated content | 1 (14.3) | 19 (20.4) | 1.16 (0.07–19.79) | 1.000 | |
Others | 0 (0) | 6 (6.5) | - | 1.000 | |
Health professionals | 1 (14.3) | 22 (23.7) | 1 | ||
Recommendations for people with diabetes mellitus | Mass media | 13 (61.8) | 38 (48.1) | 1.63 (0.47–5.66) | 0.558 |
User-generated content | 2 (9.5) | 18 (22.8) | 0.53 (0.09–3.24) | 0.669 | |
Others | 2 (9.5) | 4 (5.1) | 2.38 (0.32–17.74) | 0.575 | |
Health professionals | 4 (19.1) | 19 (24.0) | 1 | ||
Recommendations for all people older than 6 months | Mass media | 3 (27.3) | 48 (53.9) | 0.14 (0.03–0.62) | 0.008 |
User-generated content | 0 (0) | 20 (22.5) | - | 0.010 | |
Others | 1 (9.1) | 5 (5.6) | 0.46 (0.05–4.67) | 0.647 | |
Health professionals | 7 (63.6) | 16 (18.0) | 1 | ||
Costs of the vaccine | Mass media | 11 (61.0) | 40 (48.8) | 0.99 (0.29–3.27) | 0.987 |
User-generated content | 1 (5.6) | 19 (23.2) | 0.19 (0.02–1.78) | 0.192 | |
Others | 1 (5.6) | 5 (6.1) | 0.72 (0.07–7.66) | 1.000 | |
Health professionals | 5 (27.8) | 18 (21.9) | 1 | ||
Description of the dosage | Mass media | 9 (64.3) | 42 (48.8) | 0.77 (0.23–2.63) | 0.679 |
User-generated content | 0 (0) | 20 (23.3) | - | 0.051 | |
Others | 0 (0) | 6 (7.0) | - | 0.553 | |
Health professionals | 5 (35.7) | 18 (20.9) | 1 | ||
Hoaxes and conspiracy theories | Mass media | 2 (10.5) | 49 (60.5) | 0.27 (0.04–1.75) | 0.170 |
User-generated content | 14 (73.7) | 6 (7.4) | 15.56 (3.32–72.93) | 0.000 | |
Others | 0 (0) | 6 (7.4) | - | 1.000 | |
Health professionals | 3 (15.8) | 20 (24.7) | 1 |
Tone | Country of Publication | Available, n (%) | Unavailable, n (%) | OR (95% CI) a | p |
---|---|---|---|---|---|
Positive tone of the message | Spain | 6 (9.2) | 10 (28.6) | 0.19 (0.06–0.61) | 0.003 |
United States of America | 7 (10.8) | 4 (11.4) | 0.56 (0.15–2.16) | 0.399 | |
Others/Unknown | 2 (3.1) | 5 (14.3) | 0.13 (0.02–0.73) | 0.009 | |
Hispanic American countries | 50 (76.9) | 16 (45.7) | 1 |
Information Regarding Influenza Vaccine | Country of Publication | Available, n (%) | Unavailable, n (%) | OR (95% CI) a | p |
---|---|---|---|---|---|
Benefits of the vaccine | Spain | 6 (10.2) | 10 (24.4) | 0.32 (0.10–0.99) | 0.044 |
United States of America | 8 (13.6) | 3 (7.3) | 1.43 (0.35–5.90) | 0.625 | |
Others/Unknown | 2 (3.4) | 5 (12.2) | 0.21 (0.04–1.19) | 0.060 | |
Hispanic American countries | 43 (72.9) | 23 (56.1) | 1 | ||
Adverse effects of the vaccine | Spain | 8 (20.5) | 8 (13.1) | 1.75 (0.58–5.26) | 0.319 |
United States of America | 5 (12.8) | 6 (9.8) | 1.46 (0.40–5.29) | 0.567 | |
Others/Unknown | 2 (5.1) | 5 (8.2) | 0.7 (0.13–3.89) | 0.684 | |
Hispanic American countries | 24 (61.5) | 42 (68.9) | 1 | ||
Recommendations for pregnancy b | Spain | 4 (9.8) | 12 (20.3) | 0.33 (0.09–1.14) | 0.073 |
United States of America | 4 (9.8) | 7 (11.9) | 0.57 (0.15–2.14) | 0.405 | |
Others/Unknown | 0 (0) | 7 (11.9) | - | 0.012 | |
Hispanic American countries | 33 (80.5) | 33 (55.9) | 1 | ||
Recommendations for children c | Spain | 0 (0) | 16 (23.9) | - | 0.000 |
United States of America | 1 (3.0) | 10 (14.9) | 0.11 (0.01–0.88) | 0.015 | |
Others/Unknown | 0 (0) | 7 (10.4) | - | 0.015 | |
Hispanic American countries | 32 (97.0) | 34 (50.7) | 1 | ||
Recommendations for people aged 60/65 or older | Spain | 4 (10.5) | 12 (19.4) | 0.33 (0.09–1.14) | 0.073 |
United States of America | 1 (2.6) | 10 (16.1) | 0.1 (0.01–0.83) | 0.012 | |
Others/Unknown | 0 (0) | 7 (11.3) | - | 0.012 | |
Hispanic American countries | 33 (86.8) | 33 (53.2) | 1 | ||
Recommendations for people with chronic lung diseases | Spain | 2 (9.5) | 14 (17.7) | 0.38 (0.08–1.85) | 0.219 |
United States of America | 1 (4.8) | 10 (12.7) | 0.27 (0.03–2.24) | 0.198 | |
Others/Unknown | 0 (0) | 7 (8.9) | - | 0.114 | |
Hispanic American countries | 18 (85.7) | 48 (60.8) | 1 | ||
Recommendations for people with chronic cardiovascular disease | Spain | 2 (10.0) | 14 (17.5) | 0.38 (0.08–1.85) | 0.219 |
United States of America | 0 (0) | 11 (13.8) | - | 0.049 | |
Others/Unknown | 0 (0) | 7 (8.8) | - | 0.114 | |
Hispanic American countries | 18 (90.0) | 48 (60.0) | 1 | ||
Recommendations for people with cancer | Spain | 1 (7.1) | 15 (17.4) | 0.27 (0.03–2.25) | 0.203 |
United States of America | 0 (0) | 11 (12.8) | - | 0.109 | |
Others/Unknown | 0 (0) | 7 (8.1) | - | 0.198 | |
Hispanic American countries | 13 (92.9) | 53 (61.6) | 1 | ||
Recommendations for people with obesity | Spain | 0 (0) | 16 (18.4) | - | 0.054 |
United States of America | 0 (0) | 11 (12.6) | - | 0.109 | |
Others/Unknown | 0 (0) | 7 (8.0) | - | 0.198 | |
Hispanic American countries | 13 (100) | 53 (60.9) | 1 | ||
Recommendations for healthcare workers | Spain | 3 (16.7) | 13 (15.9) | 0.79 (0.19–3.12) | 0.732 |
United States of America | 0 (0) | 11 (13.4) | - | 0.080 | |
Others/Unknown | 0 (0) | 7 (8.5) | - | 0.159 | |
Hispanic American countries | 15 (83.3) | 51 (62.2) | 1 | ||
Recommendations for people with HIV d | Spain | 0 (0) | 16 (17.6) | - | 0.194 |
United States of America | 0 (0) | 11 (12.1) | - | 0.343 | |
Others/Unknown | 0 (0) | 7 (7.7) | - | 0.586 | |
Hispanic American countries | 9 (100) | 57 (62.6) | 1 | ||
Recommendations for people with chronic kidney disease | Spain | 0 (0) | 16 (17.2) | - | 0.336 |
United States of America | 0 (0) | 11 (11.8) | - | 0.584 | |
Others/Unknown | 0 (0) | 7 (7.5) | - | 1.000 | |
Hispanic American countries | 7 (100) | 59 (63.5) | 1 | ||
Recommendations for people with diabetes mellitus | Spain | 2 (9.5) | 14 (17.7) | 0.38 (0.08–1.85) | 0.219 |
United States of America | 1 (4.8) | 10 (12.7) | 0.27 (0.03–2.24) | 0.198 | |
Others/Unknown | 0 (0) | 7 (8.9) | - | 0.114 | |
Hispanic American countries | 18 (85.7) | 48 (60.8) | 1 | ||
Recommendations for all people older than 6 months | Spain | 1 (9.1) | 15 (16.9) | 0.42 (0.05–3.59) | 0.421 |
United States of America | 1 (9.1) | 10 (11.2) | 0.63 (0.07–5.56) | 0.679 | |
Others/Unknown | 0 (0) | 7 (7.9) | - | 0.300 | |
Hispanic American countries | 9 (81.8) | 57 (64.0) | 1 | ||
Costs of the vaccine | Spain | 1 (5.6) | 15 (18.3) | 0.19 (0.02–1.57) | 0.093 |
United States of America | 0 (0) | 11 (13.4) | - | 0.058 | |
Others/Unknown | 0 (0) | 7 (8.5) | - | 0.128 | |
Hispanic American countries | 17 (94.4) | 49 (59.8) | 1 | ||
Description of the dosage | Spain | 0 (0) | 16 (18.6) | - | 0.054 |
United States of America | 1 (7.1) | 10 (11.6) | 0.41 (0.05–3.48) | 0.402 | |
Others/Unknown | 0 (0) | 7 (8.1) | - | 0.198 | |
Hispanic American countries | 13 (92.9) | 53 (61.6) | 1 | ||
Hoaxes and conspiracy theories | Spain | 6 (31.6) | 10 (12.4) | 6.0 (1.61–22.34) | 0.004 |
United States of America | 4 (21.0) | 7 (8.6) | 5.71 (1.29–25.29) | 0.031 | |
Others/Unknown | 3 (15.8) | 4 (4.9) | 7.5 (1.35–41.72) | 0.036 | |
Hispanic American countries | 6 (31.6) | 60 (74.1) | 1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hernández-García, I.; Giménez-Júlvez, T. YouTube as a Source of Influenza Vaccine Information in Spanish. Int. J. Environ. Res. Public Health 2021, 18, 727. https://doi.org/10.3390/ijerph18020727
Hernández-García I, Giménez-Júlvez T. YouTube as a Source of Influenza Vaccine Information in Spanish. International Journal of Environmental Research and Public Health. 2021; 18(2):727. https://doi.org/10.3390/ijerph18020727
Chicago/Turabian StyleHernández-García, Ignacio, and Teresa Giménez-Júlvez. 2021. "YouTube as a Source of Influenza Vaccine Information in Spanish" International Journal of Environmental Research and Public Health 18, no. 2: 727. https://doi.org/10.3390/ijerph18020727
APA StyleHernández-García, I., & Giménez-Júlvez, T. (2021). YouTube as a Source of Influenza Vaccine Information in Spanish. International Journal of Environmental Research and Public Health, 18(2), 727. https://doi.org/10.3390/ijerph18020727